EUCTR2013-002611-96-ES
进行中（未招募）
不适用
Pilot study to determine the efficacy of anakinra (antagonist of interleukin-1 receptor) administered for 3 months in improving inflammatory signs observed by MRI in patients with erosive/inflammatory hand osteoarthritis.
适应症Patients with erosive/inflammatory hand osteoarthritis.Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
相关药物Kineret
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- Patients with erosive/inflammatory hand osteoarthritis.
- 发起方
- Consorci Mar Parc de Salut de Barcelona (Parc de Salut MAR)
- 状态
- 进行中（未招募）
- 最后更新
- 12年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •\-Patients over 18 years at the moment of the selection visit.
- •\-Patients with erosive osteoarthritis of the interphalangeal joints with significant clinical activity acording to Anandarajah criteria.
- •\- Important functional repercussions despite the conventional treatment reflected with a score 24 or more on the AUSCAN questionaire.
- •\- Patients who can understand the study implications thus they are able to give the written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 35
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 15
排除标准
- •Related to the study
- •\-Pregnant or breast\-feeding.
- •\-Women of childbearing potential and sexually active not compliant with adequate contraceptive measures during the study.
- •\-Participation in any clinical investigation within 3 months prior to drug administration
- •\-Patients with scheduled surgery during the study.
- •\-History of drug abuse.
- •\-Patients with any restrictions related to the NMR test
- •Related to the medical history:
- •\-History of malignancy within the last five years.
- •\-Fibromyalgia and / or chronic fatigue syndrome.
结局指标
主要结局
未指定
相似试验
进行中（未招募）
1 期
Stydy to evaluate the efficacy and security of anakinra for the treatment of unresponsiveness arthritis to conventional treatment in systemic lupus erythematosusSystemic lupus erythematosusMedDRA version: 14.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2011-005392-16-ESDr Josep Ordi Ros
尚未招募
2 期
Agnikarma in disc prolapse.Health Condition 1: M511- Thoracic, thoracolumbar and lumbosacral intervertebral disc disorders with radiculopathyCTRI/2022/11/047012Shalu mol S
已完成
2 期
Management of avascular necrosis of femoral head in AyurvedaHealth Condition 1: M95-M95- Other disorders of the musculoskeletal system and connective tissueCTRI/2021/03/031621All India Institute of Ayurveda15
尚未招募
2 期
Treatment of Diabetic Peripheral Neuropathy through ayurvedic line of management.Health Condition 1: E114- Type 2 diabetes mellitus with neurological complicationsCTRI/2023/10/058822Dr H S Harshitha
招募中
2 期
Pilot cml autograft/glivec (STI571)/Intron A trialAdvanced phase chronic myeloid leukaemiaPh-positive acute lymphoblastic leukemiaCancer - Leukaemia - Acute leukaemiaACTRN12605000071628Australasian Leukaemia and Lymphoma Group48